The psychosis risk factor RBM12 encodes a novel repressor of GPCR/cAMP signal transduction

• Published in: The Journal of biological chemistry Vol. 299; no. 9; p. 105133
• Main Authors: Semesta, Khairunnisa M., Garces, Angelica, Tsvetanova, Nikoleta G.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2023; American Society for Biochemistry and Molecular Biology
• Subjects: Adenylyl Cyclases - genetics; Adenylyl Cyclases - metabolism; Cyclic AMP - antagonists & inhibitors; Cyclic AMP - genetics; Cyclic AMP - metabolism; Cyclic AMP-Dependent Protein Kinases - genetics; Cyclic AMP-Dependent Protein Kinases - metabolism; Gene Expression Regulation, Enzymologic - genetics; HEK293 Cells; Humans; Neurons - physiology; Psychotic Disorders - genetics; RNA-Binding Proteins - genetics; RNA-Binding Proteins - metabolism; Signal Transduction - genetics; BDNF; DMSO; GO; TBST; RRM; gRNA; PDE; DMEM; CREB; PKAcat; β2-AR; CRISPRi; hiPSC; RBM 12; GPCR; NGN2; NTC; RT-qPCR
• DOI: 10.1016/j.jbc.2023.105133
• ISSN: 0021-9258; 1083-351X

RBM12 is a high-penetrance risk factor for familial schizophrenia and psychosis, yet its precise cellular functions and the pathways to which it belongs are not known. We utilize two complementary models, HEK293 cells and human iPSC-derived neurons, and delineate RBM12 as a novel repressor of the G protein–coupled receptor/cAMP/PKA (GPCR/cAMP/PKA) signaling axis. We establish that loss of RBM12 leads to hyperactive cAMP production and increased PKA activity as well as altered neuronal transcriptional responses to GPCR stimulation. Notably, the cAMP and transcriptional signaling steps are subject to discrete RBM12-dependent regulation. We further demonstrate that the two RBM12 truncating variants linked to familial psychosis impact this interplay, as the mutants fail to rescue GPCR/cAMP signaling hyperactivity in cells depleted of RBM12. Lastly, we present a mechanism underlying the impaired signaling phenotypes. In agreement with its activity as an RNA-binding protein, loss of RBM12 leads to altered gene expression, including that of multiple effectors of established significance within the receptor pathway. Specifically, the abundance of adenylyl cyclases, phosphodiesterase isoforms, and PKA regulatory and catalytic subunits is impacted by RBM12 depletion. We note that these expression changes are fully consistent with the entire gamut of hyperactive signaling outputs. In summary, the current study identifies a previously unappreciated role for RBM12 in the context of the GPCR–cAMP pathway that could be explored further as a tentative molecular mechanism underlying the functions of this factor in neuronal physiology and pathophysiology.